This report from WifOR analyzes the economic impacts of the global pharmaceutical industry, focusing on contributions to Gross Domestic Product (GDP), job creation, and research and development (R&D) activities.
Read more
This external study, developed by The European House – Ambrosetti and supported by IFPMA and Vaccines Europe, underscores the critical role of preventive healthcare, particularly immunisation, in ensuring the economic sustainability of EU health systems. The report highlights that embedding preventive measures into fiscal policies can alleviate pressures from demographic and epidemiological transitions, contributing to...
Read more
In a new position paper, IFPMA explores some of the challenges in ensuring access to safe and quality-assured antibiotics and propose a set of policy changes for consideration.
Read more
Access to information, including the assessment documents of reference national regulatory agencies (NRA), is a key enabler of regulatory risk-based decision making. It promotes an understanding of what was reviewed by the reference NRA, provides a rationale for decision making and promotes confidence and trust. The Centre for Innovation in Regulatory Science (CIRS) has published...
Read more
IFPMA has partnered with DCVMN to share our industry’s expertise in vaccine development and manufacturing. This presentation illustrates the key stages and timeline to bring vaccines to the market.
Read more
In a new report, IFPMA reviews the antibiotic pipeline data against bacterial pathogens identified by the WHO and other public health agencies as of the greatest concern, and presents modelling data on the future of the pipeline.
Read more
Ahead of negotiations on a Global Plastics “Instrument”, the innovative pharmaceutical industry put together its position. Key takeaways include: IFPMA supports an overall ambitious UN Global Plastics “Instrument” that creates globally harmonized plastic regulations. This is key to securing the scale and effect needed if we are to succeed in transitioning away from plastic where...
Read moreThe evolving global pharmaceutical regulatory environment and the increasing interest of new countries in joining the ICH highlights the importance of maintaining consistent interpretation and implementation of ICH guidelines among industry and regulatory authorities worldwide. The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), along with other ICH Members and Observers, has an important role...
Read more
Download this OHE report, commissioned by IFPMA, to learn more about the socio-economic value of adult vaccination programems on individual lives and societies at large.
Read more
This position paper outlines some key regulatory agilities implemented in areas such as research and development, regulatory evaluations, authorizations, and post-approval changes (PACs) and labelling. Key learnings and recommendations to enhance regulatory frameworks in the future are also included.
Read more
This report aims to explore the perspective of members of NRAs on the use of regulatory agilities which emerged during the COVID-19 pandemic and describe lessons learnt from this experience.
Read more
In view of a growing complexity of product lifecycle management, industry puts forward perspectives to support the harmonization of regulatory requirements. These are intended to facilitate efficient regulatory review and approval to support timely implementation of changes and product improvements, leading to more resilient supply chains.
Read more